Literature DB >> 19156375

[Catheter ablation for atrial fibrillation: clinically established or still an experimental method?].

Stephan Willems1, Boris Hoffmann, Daniel Steven, Imke Drewitz, Helge Servatius, Kai Müllerleile, Thomas Meinertz, Thomas Rostock.   

Abstract

Interventional treatment for atrial fibrillation (AF) has been introduced as a therapeutic option soon after the pulmonary veins (PV) have been discovered as the dominant sources of paroxysmal atrial fibrillation (PAF). Elimination of PV conduction is the initial goal during catheter ablation in this setting. The success rate after the initial procedure varies between 60% and 85%, with > 80% after subsequent interventions. Supported by the current guidelines, interventional treatment of AF is indicated in case of symptomatic arrhythmias refractory to antiarrhythmic treatment. The introduction of the combined, stepwise approach has been another important breakthrough with regard to the treatment of chronic persistent atrial fibrillation (CAF). This strategy includes the combination of all conventional ablation strategies (pulmonary vein isolation [PVI], defragmentation, linear ablation) with the goal of AF termination by radiofrequency current. The first procedure for CAF treatment is quite frequently also only the first step toward stable sinus rhythm with a favorable outcome after AF termination (> 80% sinus rhythm). In more than half of the patients predominantly atrial arrhythmias other than AF have to be targeted in a second procedure. This approach is currently under clinical investigation and so far not "clinically established" due to the fact that it is a quite time-consuming and challenging procedure even in experienced centers. Future studies may help to identify predictors for procedure failure (e.g., left atrial size, AF duration, atrial cycle length) in order to improve patient selection. Additionally, it has to be underscored, that in PAF the relatively high recurrence rate after the first procedure still is the subject of further investigations. This aspect might be improved by the introduction of novel strategies (i.e., testing of concealed PV conduction after ablation with adenosine) or technologies (i.e., robotic navigation) for PAF ablation.

Entities:  

Mesh:

Year:  2008        PMID: 19156375     DOI: 10.1007/s00059-008-3150-0

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  9 in total

1.  [Structural and procedural quality of different orthopaedic rehabilitation settings: A comparison].

Authors:  S Dietsche; W Bürger; M Morfeld; U Koch
Journal:  Rehabilitation (Stuttg)       Date:  2002 Apr-Jun       Impact factor: 1.113

2.  [Cost-benefit evaluation of medical rehabilitation by social security pensions and effects of the growth and occupational rehabilitation regulation (WFG)].

Authors:  T Hansmeier; W Müller-Fahrnow; H Klosterhuis; K Spyra
Journal:  Z Gerontol Geriatr       Date:  1997-12       Impact factor: 1.281

3.  [Short term results of outpatient vs. inpatient rehabilitation after stroke].

Authors:  F Bölsche; U Hasenbein; H Reissberg; W Lotz-Rambaldi; C-W Wallesch
Journal:  Rehabilitation (Stuttg)       Date:  2002 Apr-Jun       Impact factor: 1.113

4.  [Outpatient and inpatient neurological rehabilitation--a follow-up comparison].

Authors:  P W Schönle
Journal:  Rehabilitation (Stuttg)       Date:  2002 Apr-Jun       Impact factor: 1.113

5.  [Outpatient orthopaedic rehabilitation: treatment, outcomes and costs as compared to inpatient rehabilitation].

Authors:  B Bührlen; W H Jäckel
Journal:  Rehabilitation (Stuttg)       Date:  2002 Apr-Jun       Impact factor: 1.113

6.  [Outcomes of cardiac rehabilitation treatment and cost-effectiveness relations--A comparison between inpatient and outpatient rehabilitation programmes].

Authors:  A Vom Orde; T Schott; O Iseringhausen
Journal:  Rehabilitation (Stuttg)       Date:  2002 Apr-Jun       Impact factor: 1.113

7.  [Outpatient and inpatient orthopaedic rehabilitation--results of a study comparing outcome and costs].

Authors:  W Bürger; S Dietsche; M Morfeld; U Koch
Journal:  Rehabilitation (Stuttg)       Date:  2002 Apr-Jun       Impact factor: 1.113

8.  [Economic efficiency of outpatient rehabilitation -- final results of a study in Mecklenburg-Vorpommern].

Authors:  H E Klingelhöfer; A Timm
Journal:  Rehabilitation (Stuttg)       Date:  2005-02       Impact factor: 1.113

Review 9.  [Cost/benefit relations: evaluation of inpatient and ambulatory rehabilitation].

Authors:  W Kübler; J Niebauer; J Kreuzer
Journal:  Z Kardiol       Date:  1994
  9 in total
  6 in total

Review 1.  Wnt-frizzled signaling to G-protein-coupled effectors.

Authors:  H-Y Wang; C C Malbon
Journal:  Cell Mol Life Sci       Date:  2004-01       Impact factor: 9.261

2.  Image of the month. Massive right atrial thrombus due to heparin-induced thrombocytopenia type II.

Authors:  K R Julian Chun; Dietmar Bänsch; Rudolf Bauer; Carsten Schneider; Karl-Heinz Kuck
Journal:  Herz       Date:  2008-09       Impact factor: 1.443

3.  Cryoballoon in atrial fibrillation ablation.

Authors:  M Schmidt; U Dorwarth; F Straube; M Wankerl; J Krieg; A W Leber; A Huber; E Hoffmann
Journal:  Herz       Date:  2012-03       Impact factor: 1.443

4.  [Molecular mechanisms of atrial fibrillation: potential role of microRNAs as new therapeutic targets and potential biomarkers].

Authors:  R Wakili; S Clauß; S Kääb
Journal:  Herz       Date:  2012-03       Impact factor: 1.443

5.  Robotically controlled ablation for atrial fibrillation: the first real-world experience in Africa with the Hansen robotic system.

Authors:  Faizel Lorgat; Evan Pudney; Helena van Deventer; Sam Chitsaz
Journal:  Cardiovasc J Afr       Date:  2012-03-23       Impact factor: 1.167

6.  Predicting successful pulmonary vein isolation in patients with atrial fibrillation by brain natriuretic Peptide plasma levels.

Authors:  Dong-In Shin; Thomas Deneke; Eduard Gorr; Helge Anders; Kathrin Buenz; Marcus Paesler; Marc Horlitz
Journal:  Indian Pacing Electrophysiol J       Date:  2009-09-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.